Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

pSivida breaks BrachySil into Chinese market - correction:

This article was originally published in Clinica

Executive Summary

In Clinica No 1180 (November 4 2005), we stated erroneously on page 14 that Perth, Western Australia-based pSivida was to pay Beijing Med-Pharm upfront and milestone payments totalling more than $2m for the distribution of pSivida's BrachySil in China. This should have read that pSivida will receive upfront and milestone payments from Beijing Med-Pharm for BrachySil. The modified silicon product that is just entering phase IIb trials as a potential new treatment for primary liver cancer.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel